RT Journal Article
T1 Multicenter experience with a second- generation fully-retrievable and repositionable transcatheter aortic valve
A1 Gemma, Daniele
A1 Moreno, Raul
A1 Larman, Mariano
A1 Teles, Rui Campante
A1 Patricio, Lino
A1 Molina, Eduardo
A1 Ribeiro, Vasco Gama
A1 Del Blanco, Bruno Garcia
A1 Granado, Roque Arana
A1 Valero, Santiago Jimenez
A1 Galeote, Guillermo
A1 Hernandez, Harold
A1 Irazusta Cordoba, Francisco Javier
A1 Serra, Vicenc
A1 Lopez-Sendon, Jose Luis
K1 Transcatheter Aortic Valve.
K1 Aortic Stenosis
AB Introduction and objectives: The Lotus Valve device (Boston Scientific) is a second-generation fully-retrievable and repositionable transcatheter aortic valve. We report the initial multicenter experience with the Lotus valve in the management of patients with severe aortic stenosis. Methods: Observational study that described the short and long-term results of implanting the Lotus valve in 8 Spanish and Portuguese centers from March 2014 through April 2016. Results: The study included 102 patients (mean age 80.4 +/- 6.1 years; STS score 5.2% +/- 3.3%) with severe symptomatic aortic stenosis (mean aortic valve area 0.66 +/- 0.17 cm(2), aortic gradients 74.3 / 45.6 mmHg). The valve was successfully implanted in 100 patients (98%), with significant improvement in both the peak and mean aortic valve gradients and with only one patient showing moderate paravalvular regurgitation. Upon hospital discharge, mortality rate was 3.9% while the stroke rate was 2.9%. No cases of valve embolization, ectopic valve deployment or additional valve implantation (valve-in-valve) were seen. Thirty-three patients (32.3%) received a permanent pacemaker. Conclusions: The Lotus Valve System is effective and safe for the management of patients with severe symptomatic aortic stenosis. In particular, considering the low rate of periprosthetic regurgitation and lack of complications like embolization or ectopic valve deployment; however at the expense of a high pacemaker implantation rate.
PB Permanyer publ
SN 2604-7306
YR 2020
FD 2020-04-01
LK https://hdl.handle.net/10668/26312
UL https://hdl.handle.net/10668/26312
LA en
DS RISalud
RD Apr 11, 2025